Legal Representation
Attorney
Tiffany D. Gehrke
USPTO Deadlines
Application History
46 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 19, 2022 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Dec 19, 2022 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Apr 15, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 14, 2022 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Apr 7, 2022 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Apr 14, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Apr 7, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 3, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 1, 2021 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Nov 1, 2021 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Nov 1, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 16, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 14, 2021 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Apr 14, 2021 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Apr 14, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 7, 2021 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Apr 7, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Apr 7, 2021 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Nov 13, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 11, 2020 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 11, 2020 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Nov 11, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 5, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Aug 5, 2020 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | Loading... |
| Aug 5, 2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Aug 5, 2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| May 13, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 11, 2020 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 11, 2020 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| May 11, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 12, 2019 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 17, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 17, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 28, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 13, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Aug 6, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 2, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 1, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 1, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Apr 26, 2019 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Apr 26, 2019 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Apr 24, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 24, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 24, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 19, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 5, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Detailed Classifications
Class 005
Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer
Class 042
Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development
Classification
International Classes
005
042